Loading...
Docoh

Aptose Biosciences (APTO)

Participants
Susan Pietropaolo SMP Communications
William Rice Chairman, President and CEO
Gregory Chow EVP and CFO
Rafael Bejar SVP and CMO
Jotin Marango SVP and CBO
Tyler Van Buren Piper Sandler
John Newman Canaccord
Gregory Renza RBC Capital Markets
Matt Biegler Oppenheimer
Naureen Quibria Maxim Group
Matthew Cross JonesTrading
Call transcript
Due to licensing restrictions, you must log in to view earnings call transcripts.
Operator

Good afternoon. My name is Jimmy and I will be your conference operator today. I would like to welcome everyone to the Aptose Biosciences Conference Call for the First Quarter Ended March 31st, 2020. At this time, all participants are in listen-only mode. After the speakers' remarks, there will be a question-and-answer session. you. Thank Instructions] [Operator

this may reminder, recorded. conference a be call As

Susan to go I like Ms. Pietropaolo. would now introduce Please, ahead.

Susan Pietropaolo

the and Thank you, conference results XXst, financial Biosciences Biosciences. Susan for Pietropaolo, to welcome ended a for XXXX. operational communications I'm Jimmy. Good call afternoon to and first March quarter Aptose representative Aptose discuss

Marango, Chief Joining me and are Chief Mr. Officer; Chow, Gregory today Officer; CEO; Vice Rafael President Financial G. Bejar, and President, William Officer. President, on Dr. the Senior Dr. Dr. and Chief Jotin Executive Business call President Rice, Vice Vice Senior Chairman, Medical

Before to forward-looking statements statements certain I and we include meaning during the laws. proceed, U.S. of would remind everyone within will Canadian like this call securities that

events, and performance expectations. of but are reflect statements these materially Forward-looking not it results and possible future performance, that could actual differ stated from Aptose's current regarding is guarantees expectations

from results, Aptose's more and They cause achievement SEDAR read Annual to involve and uncertainties uncertainties, in and factors that assumptions the materially Form on Report known recent expressed. SEC filings. unknown please and risk actual set and performance, these and risks those forth To most may risks, differ XX-K about learn

made date update undertakes during call, as speak All forward-looking the of reflect after made. date statements of no required law. the this events except call statements to as they obligation only these to this by or Aptose are revise or circumstances

Dr. over Chairman, Rice? of call will and to Biosciences. Rice, now the turn I Dr. Aptose President, CEO

William Rice

our March XXXX. first ended Susan. Thank XXst, call everyone to for I'd you, the to like welcome quarter

changed in two even Although has our much was our then. prior not call ago, conference world since months

our to all safe could business, I'd on put if infected, that potential update workers, thanks and of compassion I Aptose like you of heartfelt on to those our you are Before and hope healthy. our all who healthcare COVID-XX our to have our any, impact on express and are

headwinds experienced each others that unique force hematologic many cancers not several the is as or you and is are and issues, in facing. the treatment patients enrollment treatment. to know, with Where cancers. needs halted other that fortunate APTO-XXX and have have is are is to companies CG-XXX Because significant address experiencing each trials We of to biotech of to full molecule be situation quite Aptose clinical unmet not hematologic company developing patients tend these elected. ill, Aptose or postponed

despite been CG-XXX investigators pandemic, patients Consequently, for I enroll, myelosuppressive. recent our has induced consideration continuing prospective Phase trials immunosuppression. nor importantly An and APTO-XXX And during clinical neither to-date, that clinical are important has this to events. is neither

Many healthcare this approved patients potentially development cancer both crisis. even for in immunosuppression, risk but can more therapies general, elevating cause so under and during

call Now, as just will let's first the impact or I CG-XXX of XXX, on consider COVID-XX potential it.

that address We addressed challenges and have to disruption. could cause continue

We far, B-cell no have call material you crosswinds delays ongoing experienced will these we our trial. if will, malignancy but in thus

the accommodate Our clinicians, and the team and challenges and as our challenges appropriately, patients, ensure safeguards to new procedures to due COVID-XX. employees the potential top swiftly addressed safety implementing and proactively these of priority

headwinds more XXX, than crosswinds experiencing we're and XXX. to With of relates properties rather the that

and visits directly thereby XXX to need the capsules ship the reducing of example, can orally we is for For clinical bottles administered, patients, sites. to

in and site the site reduces hospital allows visits. and them resources observations each to real-time enabled also or Patients and potential We risk exposure of COVID-XX. upload This which data receive iPad, appreciative. reduces remote the also are clinical an patients' greatly had again to monitoring, reduces which

labs by once-a-week for on We of local relying blood draws, monitoring. also number site safety reduce all can not the by additional of typical requiring and visits the

disruptions. our proactively avoid also potential with assess to manufacturers contact are chain drug We in supply and constant

drugs, of not enrolling patients have we adaptation cancer the on are manufacturing have academic actually focus institution. drug focusing is greater and the large rather on from in such our regional now that One far, placing fact hospitals and Thus we product experienced specialty accelerated. key any centers, disruptions than

This and many rooms the units, enroll disease sites is trials. and academic in to have emergency challenges treating COVID-XX face large infectious clinical patients of because safely patients

sites that us lower contrast, Such anticipated cancer enrollment treated and of are and rate, the their based they well clinics. coming rapid on track. infection In continue enroll most the overnight to an patients, represents to regional a COVID-XX patients has not of both served into bandwidth pivot to our we on have adaptation risk

typical oncogenic resistance. compared or it BTK of only development, you a inhibitor, than on forms drug to as asset which survival inhibits is and most who this FLTX, haven't, pathways, suppresses wall those much multiple more signaling not and mutant have you and of simultaneously for this distinct or that an of under clinical for therapies cancer commercialized XXX before, cells type FLTX heard Regarding other rely XXX and are a it is update potently Many BTK upon development. but

the compound. toxicity. of to It development, XXX that unparalleled AML, avoids leukemia targets is that FLTX, other surrounding This the this acute associated what with hematology drugs often much are including in the sets known contributing malignancy of B-cell targets singular compound yet and a primary the with and or on BTK selectivity market and drivers excitement from apart profile myeloid or precision that is

on BID XXX treatment let's levels about XXX, and one speak including administration Now, NHL non-Hodgkin's our or I'll Lymphomas, four focus study and of through of CLL XXX, I that the with patients milligrams respectively. dose XXX, today just and cancers, Phase the involve B-cell of XXX,

on the fourth our Committee milligrams. escalation supported we XXX XXth, unanimously level with dose March those our to Cohort completed call, And XXX with the successfully Review milligrams. Safety third Since levels last

at three XX XXX well. patient XXX patient that and pleased are completed one a level dose we has dosed milligrams is trial level began has per on and performing at dose Also now protocol, that dose level been escalated receiving that who to preceding and the milligrams cycles first dose this our

completion doses, be to of with commenced dose at well-tolerated. three, we level milligrams. quickly on continues XXX these even dose XXX patient To-date level treatment Following four higher

details let's of a at already to-date. an patient enrolled phenotype. study The milligrams, CLL on study cohorts very in FLL Now, the this first with few patient's XXX patient [Indiscernible] discuss is the has

we that steady-state At level, of in the the achieved exposure minimum in plasma observed level This dose represents a micromolar. steady-state the X.X over time. plasma level approximately

assay. patient the it cells. we and it collected on we plasma PIA plasma inhibitory place patients, a from our assay, in tested Importantly, PIA first this labs, or collect that from reporter activity, the into plasma With return and

is plasma plasma XXX, of in to We inhibit S-Y-K. wants in to spelled including biomarkers, one. patient observed pharmacodynamic of markers achieve hours, the inhibited there with steady-state the these plasma sufficient PIA drug of all to the level determine few phosphorylation assay. BTK, And a and ERK, After we that levels SYK, the western dose use is blotting that if key PDGFR-alpha, that's

At cellular lymphocytosis a level, CLL from observed Concurrently, the effect we classically BTK. of a we that BTK had the patient, patient of indicated and a to observed the that rapid one pharmacologically-active inhibition of inhibition second the we patient's of dose PBMCs response at achieved XXX% bloodstream. exposure described With dramatic in phosphorylation as is placed a on study. CLL XXX been

SYK, micromolar PDGFR-alpha XXX inhibiting capable in the the of and BTK, of XXX PIA the Moreover, of reporter the one fully And levels approach steady-state plasma of phosphorylation ERK, assay cells. the that were levels in range. revealed

follicular evaluating two two and milligrams, level lymphoma XX-day moved dose with with XXX the cycle, patients at dose which we data enrolled from one After XXX patient. the level completed to and SLL with milligrams, three, we

the data level a result, As quickly necessary we collected that completed safely. and and dose

Although, that XXX well-tolerated. presentation as level that were steady-state the the the inhibited one the expected will drug micromolar we was the plasma the those the The range not PK embargoed EHA now levels markers say we at in and and PIA are the Conference data can June, discuss and PD in well-behaved of quantitatively, assay. in data circa for

After cycle XXX dose escalated milligrams. milligrams, the which XX-day XXX dose we with on the at successful patients three completion of patients level with third receive then would dose four, level to the

continue we continues be in this At and dose cohort well-tolerated. this time to to XXX

with that Conference. will once While are findings until findings to share levels embargoed dose pleased three the four, we you unable dose thus again the EHA far are we these levels quite we remind from with and

Provided in four to dose expansion dosing plan recommended level, complete Phase malignancies. of XXX to with we escalate studies. ultimately XX patients XXX for milligram in clinical up successfully three we dose XXX on B-cell subgroups this specific patients phase, escalation we may dose the patients milligrams determine to at at XXX across three that milligrams dose the patients II enroll activity then Depending with and

dose data that release the levels slides on recently presented Forum. Medical Chief are on Rafael Our Virtual Bejar website. the corresponding two a from the of patients Officer, first AACR our Note summary and press available Dr. during

amended were granted. virtual from to The had and the that deliver conference been format live a was we originally unable oral live we presentation to bit

five-minute and successfully. that escalate So, professionals to to for the continue indicate to summarize opportunity two we from cohorts medical utilize data first the dose virtual we

forward year. a European higher profile at the of pharmacokinetic a pharmacodynamic noted dose and in I the As complete the June, levels EHA will later and meeting Meeting at to earlier, which Hematology we be as also the in presenting known ASH virtual Association, look also more of picture

sites and for As come to scheduled the on open of enrolling with screening today, we sites have study XX additional U.S. for patients board.

B-cell more please specific sites the clinicaltrials.gov. on information malignancy enrolling trial For the visit patients, clinical and

study of to about it. on the AML our XXX support patients spoken and rationale move We've AML. application the KOL for let's before behind the Now, with

status you this the of update briefly I'll planned So, on study.

also broad spectrum, across only XXX and BTK giving the is malignancies. the activity, FLTX myeloid a lymphoid possesses both person including potential hematology inhibitory inhibitor strong therapeutic that

work, the preclinical AML with our malignancies. our it addition XXX on B-cell to always treat patients in to Based has been extensive intent

treatment were patients As you FDA had the XXX designation drug back granted by we may XXXX, AML. and for the orphan for recall, with of applied for in

a At competitive others glance, be on appears drugs market, first and horizon. to with recently the AML approved

cures benefit. these show become current refractory therapies of may and However, targeted initially Eventually, responders most clinical none offers such among in themselves. relapse and All treatments. agents to approved some

in for CLL, cancers, growing the as number a clearly with of potential believe experts to has agent and market along that that serve and AML, and XXX other is to including investigators and development, transformational industry continue from immunologic multiple others. on a agents the We, distinct

been, we in So we that big efficacy must exposure starting and dose we data what condensates AML. must for key patients? from other potent cells their believe choose kill We operative with gleaned patients safe level To a in answer our the study dose plasma that B-cell consider we will in AML dose levels, have malignancies. and has that the first with question that FLTX, AML recommend far, animal can the totality humans, this, well-tolerated and that has AML, phospho in can of is that models correlates achieved and inhibit clinical with

milligrams far, I As mentioned XXX and dose all thus up earlier, safe well-tolerated. have been levels to

care the takes safety So consideration. that of

Also, phospho same exposure steady-state level the already, plasma toxicities. steady-state and observed range exposure I we PIA that call That observed lead XXX without plasma have that to in in levels. milligram plasma other three, will cures circa AML at exposure and dose relevant XXX and the one level targets what is micromolar levels the inhibits mice and assay FLTX in

AML for the Overall, patients as based can the identified a have B-cell dose on with ongoing of and in therapeutic starting now patients pharmacodynamic from believe in we study treatment serve Phase pharmacokinetic, we Ia/b what malignancies, patients. safety, data

in to patients. the initiate relapsed FDA the to a XXX of IND the We're new and study submission [Indiscernible] and AML of clinical stages for final refractory preparing

activity to-date soon the submission same malignancies. with been I they preclinical never the agent requires the that as well are look as not to by is patients tolerability, to more we possible. point the in prepare This as submitting forward we time new IND. than first want new XXX that in move and as FDA into out IND gathered findings the IND as and consolidate to this pharmacologic PK/PD all a for of data patients safety, to to has for heartened human humans. an AML will hope This data, this But we in B-cell and findings

tier top to clinical our regional with cancer treatment trial. the sites sites team and closely AML and Finally, has identified working is initiate new institutional

allow we about is the that patients that our make features and mentioned oral, will us the be dosing before patients believe we of that begin that monitor optimistic so XXX that AML well-tolerated, All it may is can a remotely that at we therapeutic what IND dose. FDA may are

in made significant perspective COVID-XX as the malignancies on study well of year. Phase the with ongoing know we have and measures throughout forward because in B-cell as XXXX. To wrap-up recording progress on look this progress remainder Ia/b XXX, additional to arena, precautionary some already AML trial CLL we on of our We the

second MDS. or on our in inhibitor now APTO-XXX and a to for patients And currently MYC trial just AML and Ia/b first-in-class Phase clinical XXX, our with candidate

you driver major of know many of the As oncogene cancer proliferation. a cell MYC is

its fact, as cancers to estimated AML tumors. is XX% solid well up including In expression of as elevated MDS human be to and

MDS Phase protocol, refractory Per administered our relapsed with a once dose ascending maximum XX-day a AML I being cycle tolerated reached. until is doses clinical patients or weekly, at XXX high-risk over or is in

cohorts single study designed to The is in and appropriate agent as expansion AML transition MDS. to then

the on XX as as patients the the -- We last XX-day have dosing meter XX the dose, in observe square levels three mgs suppression of first to with the well-tolerated model cohorts, one today. to three XXX be cohort per patient continues dose inhibition meter at and thus fourth per mgs well continue in being no dosing XXX completed a dosing far we all square. MYC

Ia/b XXX modify for clinical. with to we to we to that encouraged continue and to learn what to trial difficult about we molecule. continues open making this best molecule. to forward deal about trial, decisions inhibition, clinically on the are continued the MYC The In a historically to We're target how learn continue expect move great observe be enrollment and Phase

consider a more may once dosing week. We than

cancer preclinical solid indications, We studies tumors. are also other pursuing and including

or the working oral future on the which drug. enrollment and safety formulation assist to hospital site and to requires we monitor each XXX environment patients. Because administered the the its impact forward may infusion, XXX, progress. pipeline is a our of candidate of an noted for intravenously, viable are resources remains thus apprised far activity of patients during clinical addition, patient's to need and of In look have keeping on it Because we an you in with we've COVID-XX

review turn the Greg President Executive now Mr. our Officer, call results the Vice of the over will Chief who to I’ll Financial Greg? and quarter. Chow,

Gregory Chow

Bill, with to and investments equivalents quarter cash at cash We everyone. afternoon, approximately XX, million million you, Thank in and the $XX and good compared $XX December ended XXXX.

increase activity and general we utilized XXX compared million attributable is the quarter, XXX year. to $X.X of and activities the in During approximately same for $X.X cash increase with million operating quarter surrounding last purposes. and The administrative

income and compared Development was the QX increase no not same trial, revenues particularly This Research year. to million $X.X the clinical of $X.X were on activities, quarter. we Moving due for quarter begin had expenses did primarily last for the to statement, to the which CG-XXX quarter, year. again until last million the for

to million quarter stock-based the G&A is million for same were expenses the $X.X for This due in primarily to compensation. compared variance quarter. increase an $X.X

Finally, $X.XX the our or for net was $XX.X loss quarter million per share.

million agreement with I terminated turn public want we Dr. we for At-The-Market million I previous Rice, as year, ATM which to new them $XX and or Canaccord Genuity the replaces back conjunction call co-agents. one to ATM a Piper into the in with offering had This last we $XX December. in entered that with Before the mention Sandler

that Although, we runway. an provide cash R&D ATM flexibility to near and plan our in maximum XXXX, a have future. fund and operations extending the don't we does into Having utilize to sufficient strategic the and ATM anytime plan

will I to over now call turn Dr. back Rice. the

William Rice

on Dr. Medical Thank Officer; Dr. the Bejar, our I'll our that Rafael you, line Officer. have Business with everyone also Greg. Marango, Chief Jotin remind us and we Chief

questions questions, feel of open the any to we for post to free As us. call

could you the first please if question. introduce Operator,

Operator

you. Thank

Van comes Piper Buren question with Sandler. from Tyler first The

line is now Your open.

Tyler Van Buren

a progress you anything that plasma four, is, the afternoon such three, in dose microliter congrats plasma is time. guess, of patients? question was period how exposure course levels? can malignancies level that the short first specifically, clarify I there say level was respect good initial dose all on and it among [indiscernible]? the B-cell stated a that with of three XXX to could and on just And with to consistent then guys, Hey respect you And you one

William Rice

to have for But called a patient's see was a it had around coming Tyler. somewhere it right. it -- over that it bit on. bit three below I With plasma among one And Thanks the micromolar, levels, was one micromolar some level a above. little bit little All somewhere three, to very we yes, consistent little circa Thanks achieved you were chatter very the -- pharmacokinetics thrilled of was all one were regards exposure we the in behaved. were time dose range. They that patients. and well micromolar

level dose say, of careful four, the patients there. be on to we we terms terms of that again, in are In have what

well happy I this for that and seeing at point, mentioned, wait As tolerated. we'll parameters patients with We're pharmacologic study. it's what to been on the very EHA. in are any But pharmacodynamic very we're this have

Tyler Van Buren

Understood.

William Rice

want Dr. add that. And to to perhaps understood a Bejar, bit may

Rafael Bejar

I three, job the in add behavior for nothing I you No, characterizing there. dose did level have patients those a think great to

William Rice

you. Thank

Tyler Van Buren

guess, And say, or dose the increase I we plasma be since you can't levels, doses. be I get into more you just state expect guess, higher potentially the exponential the throughout could as if in cohorts exposure you linear to a

William Rice

at not this do steady-state PD have from time. or point, can't we at this the PK dose levels really I level say four

So difficult we're and one that. two, any it's level very make judgment to dose one patient. only level on Dose

all range. three is and And so dose have one patients they we where three, greatest the level within expected were where have we confidence the the

level dose four. able that bit just data into yet PK/PD on we again, But more a So have to don't provide we from EHA. we'll get data be the

Tyler Van Buren

refer initial would or whether milligram. XXX potentially didn't Understood. or be which even you and level AML, with dose three the on four dose two, And XXX as but to dose, say you identified

guess, you I possible that as guys to is down it and you when use dose learn use wait approval? the what dose starting that dose? two we starting could level And is So drop have AML, a maybe for we IND in

William Rice

will dose been that has are derived completed. that What cohort is, a recommending I is we from a say

exposure We either we starting three other two dose on comfortable are those feel still the would is level dose the two so that dose pharmacodynamic activity in also would dosing down Cohort represent those. pharmacologic say and it I that to the in could cohorts. with based of What a saw level X and narrows either doses, I levels, or levels,

the are to that's based we data. the And of making we're up the recommendation get so FDA And up, all been matter submitted to the FDA. totality to of and and weeks trying on the within written a in it all

Tyler Van Buren

Okay, the helpful. taking for Thanks very questions.

William Rice

Thank you.

Operator

And with you. question John Newman our next Canaccord. Thank comes from

open. Your is now line

John Newman

Hey, Thanks guys. congrats and the on progress. for the question taking

So I I you a see but to it, of about describe us give we you as bit type to a there? and maybe wondered data Bill, EHA. that know see the just information might if generally much just just just type wondered more we sense could too you talk can't obviously if might at that as could the cohorts of speaking,

Gregory Chow

All right, John. Thanks for coming on.

So understands we've to consistent guidance. we and everyone sure been our very this, want about make

through is present Our PK, at EHA. we pharmacodynamic from Cohort X PD that data, safety, Cohort guidance and data plan X to

on required be abstracts of month the May. date of the uploaded believe the I XXth submission to for

to as get then can then this X, likely much that a posters. get data data at include If time, integrated the in through especially EHA, can that XX those them, we such we're would press far as them and there collect presented and May after between come the additional we as have Cohort time into So release. evaluate data now we that, through we to-date at trying data cleaned, to as

data. higher possibly patient getting time. see see data we're seeing responses. that responses once people a take and But dose response. achieve everything it But levels. telling we're start expect into chronic now we to at of types see these B-cell point. those this it types before But right does are you you the don't can want into We're the dose We're getting malignancy seeing in to higher take that couple hoping just months response the of to these We're get patients

Jotin Marango

I go ahead. Perhaps, Greg add alluded, -- want to

John Newman

just here before what cohort the Jotin, the at next were sorry. wonder the to enrolled, And to just could you of could you a you. on just the the remind us us that people. time was just that time study Thank is and is, way that one follow-up the trying additional dose CG-XXX of I think remind between you designed, short. relatively which specific could patients get I'm that amount just I escalation, explain if the is And question dose

William Rice

of Yes, so XX successfully that for instance, which on to -- complete complete had safely to the days. full had X, Cohort we patients them is three all study, a place and cycle,

on Now, could would enroll it a effectively three of if you all only dosing. month be one, day then patients

it then safety from can the complete that clinically to takes after And data It dosing data clinical Committee. Cohort accurate, numbers are then data ensure data, site, monitor present the weeks collect those you be Review weeks to Safety CSRC, the sizeable. PK/PD the several all the the data,

Then up CSRC, the the dose to they level. vote, next then to move presented have data to you have the

if the timeline. on one, all clearly patients accelerate So would that sense get you it that gives a could day you and three

happened. But before the or next that's entry see excluded, next immediately, before often get excluded not it it and We have the look patients, maybe but patients the bring that, to their because criteria, be There in are to many the fit we'd disease or like two two trials, but to have way other week of escalation status. of these they they we a at because data. In on, be one that one. not the just the one, you the week may actually

EHA. to patients, get bit scans just guidance a us that some you And what little the the you're these more we will many provide it get other have how sense trying as I'm we sure, closer takes. that toward a of of gives on try So and thing, on to

one, these said, get level XX in be to three, a the EHA, completed considering get XX can of a will squeaking guarantee, now dose in we environment mean, try. I to up before there, COVID to scan excuse and on for there's moved no it's a they've the try. have me, scan cycles try patient long I cohorts patients going -- we time, dose that at first But will Some level, as to been we

same is before all level four. dose The we those no I will Hopefully, true three so. from can data that we COVID And do to be scans. a and do represent EHA. But in dose guarantee environment you, the will actually then squeak couple considering possible that. level there's to get vow those able everything to can be to to able

want John. me Thank you, if teammates of right. Greg, that, I Jotin, to anything other guess, Let not. any to add Rafael. see, the All

John Newman

you. Thank

Operator

Markets. And Thank RBC from Gregory Renza question our next Capital you. comes with

Your is now open. line

Gregory Renza

I Hey, glad the connected guys. just question. that Yeah, color you environment. Bill team, environment all teaming and on June. coming the this congratulations team And into to taking Thanks in and for well up on my expectations you, with to the into the mean as appreciate EHA progress the and hear and

think the back -- disclosures sort already trial? those what you if XXX you're trial talk to ability could least about, how responses on affecting progresses reiterate how or maybe expectations half to the looking look the levels, Thanks. getting on this and been the here the where or curious, impact -- you we those how see as on of just environment provided how you've year. would as some have perhaps of And and year I'm back plan crosswind about even you respect the at the with to a about half of of at disclosure and anticipate for what touch given has at, the weathering disciplined would

William Rice

Thanks, Greg. right. All We'll do. Yeah.

there. all, City, all safe of about can in it guys hope sitting see reminds all York we're you New you me everybody thinking First I so is

in coming as Regarding to been the for EHA present June, able along just we be at I up EHA, all expect very expectations, soon. that with what to we've consistent described

present especially then, But the half see of by of doses, at had able responses. will at as we we year, doses patients get end long We to have enough correct into second expect on to data, the hope the to year. the we the be ASH higher the additional types of that

responses. Again, we're responses point, those And at except you've to for seen these BTK hope just year. other we show need And again, we able that relapsed -- this especially patients present seeing longer everything later with the them patients for start that to to responses. on takes time, to be through hope the this we this time at have inhibitors to covalent ASH refractory non-covalent for it takes deeply seeing

two Even, if only -- you every the on, for earlier scan were cycles. to a to it scans still time patients takes the get Lymphocytosis show you

a two tell that's are And apart. So response. months then only you they truly have able to whether or not

the So trial for malignancy AML. that B-cell speaks the to

possible. AML up trial and to data the AML need we it the those that put new we from trial, soon been that B-cell as all being into get ongoing as the and to running now get to submitted want soon cleaned can. We to want study. as data study, we malignancy We've are as that, collect able mentioned, I the the all of As for prospective get FDA IND the

it have the tremendous they FDA on a day will in plate, have that but Again, around XX because their we turn actually turnaround, hope I We job. days. orphan done to able today's XX they've environment FDA the lot have commend be drug in a that, we designation. the

But progress other so on no turnaround with contact been been amendments, on reports, the protocol with just we've guarantee there's so and in going we've them reports, annual forward. We've pleased activities, time. been very

you And running soon possible. as We will patients an AML as acute the disease. up get that study and to have remember, that's

month, of hopefully, you blood. truly have dose some as to effects the bone And start dosing. marrow, to the split what you the by would in you If hits seeing start peripheral second therapeutic some as we the within month well the consider three, first expect see a that can responses

be to able the in the would the that with at second present half year keep that the patients everything fingers So of crossed, end to we'll ASH, FDA. AML, be be year, get the toward your through hope what to speaks able of multiple to

variety working sites, institutions, level. well be dosing, therapeutically get dose, on. active we We're soon it major said those should patients start and to they as as as believe we of patients with we at regional again, as site, will that be And dose clinical a a three we the want

to case, earlier One choose patients into B-cell other earlier. so. dose the to one protocol I our when waiting up a dose we forgot to I malignancy to do that next levels, and three thing add, move get have level if might you're do patients, you've that CSRC to to level. for completed A mention dose amendment backfill data to allow the good trial will to us where would want do We collect you that the is,

before So next you also, the that keep we consider we'll backfilling some And dose might to patients levels. level dose on patients highest to up up can can. level, to prior the we move try moving

safe. we dose one the three, dose when and assuming four, level we up it, complete up level to So patient moved for it's instance, we complete

four. level dose and to dose We up patients one, on want dose level to move three level all

Greg. rest activities those the Appreciate the And So throughout of year. for the us, are for being thanks there types it. of

Gregory Renza

far maybe And to to what volunteer -- Thanks. impacts, curious, healthy if I'm remind in, as be more you thinking if important is you you in how us, very Thank there's should glean much. as program? we if that fully. just mentioned fits any I'm impacts. question, how the there's you the could PK/PD that that And one from characterize overall input just an there curious, trial and more if may, potential I past COVID-XX as just

William Rice

That's actually an interesting question.

rather these described headwind. as than cross we winds So

that analogy. I COVID-XX it up came Chow think what address. Greg with additional we have out is to it many was the so challenges the with there, And there's means

just and opposed still a So, different changes and to in a need still as plane, to timeline we're the plan. it to where few you that go. we're headwind able little fly pushes And maintaining on hold to we maybe really original direction you get been our back. But

don't timelines, -- the influencing this of plan. we still we're at COVID-XX see point, this So at necessarily, point, at dramatically on our any least

were as originally the of PK But get together, that additional study, both that B-cell the were PK AML study, data we data we we so be well upcoming we doing malignancy from we of should plenty able that to terms get PK/PD healthy In trials, we were need. volunteers as realized data. the considering putting we getting could trial, as that the the all

we And get perform additionally an all trials. add to your volunteer there need need to healthy questions We this doesn't believe that the the trial. that time. not current we data Does so the anything additional at from us can is really adequately? answer It

Gregory Renza

progress. Yes. helpful, congrats does. the Super Sure thanks, on again Bill and it

William Rice

Thanks, Greg.

Operator

Matt our Oppenheimer. comes And from Thank next you. question Biegler with

Your line is now open.

Matt Biegler

data questions. attention paying Bill, phospho on some addition guys. we taking my to congrats you to? the progress. of biomarkers for BTK. My other evidence for set, Hey, of should the Thanks be are lymphocytosis And EHA what think in important that

William Rice

some in that see to expect only would you is CLL patients. lymphocytosis the Well,

with a CLL then patient of treating for BTK lymphocytosis. you have a when start could active see cells inhibitor, load So with reasonable the an in that bloodstream, you instance, malignant expect comes you to in if

the something is that for that, watch are that should you watching timeframe. for, So around we definitely

in again, but at get is of close. to responses, to the scan. don't hope -- look all back up. the for What As going -- do responses, EHA. expect the a else is to to And again, we we you at have we be let can look response, to very but see me able well that timing We're for that

see expect about talked we and those don't So of types patients. to that the other lymphocytosis, you

to that to for maybe lymphoma so blood. these or patient the why because low CLL of dose for the and level current necessarily tosses load FLL them get That's types it of very see patients, then will patients patients, from was the these And a nose patients important in activity. those see types us in that was don't it forward, two. you show on even follicular going levels in and DLBCL so can patient. peripheral from it's us we also But you it get hope expect early, important Richter's, CLL would forward, going So to dose we to

from necessarily from you PBMCs these patient. to don't in to Why? the be PBMCs, if on patients particular Because lymphomas, again We collect also click of have want in to cells. get nor follicular get to you're CLL a some what's trying other on of able picture malignant that going lymphoma

that reasonable phospho dose signal, the showed up that ELISA the enough using demonstrating an that can CLL have pick a four is active. inhibition you dose you level patients, and its see PBMCs. cells, BTK if you have of assay, patients But and pharmacologically load of actually we And CLL in very of can you in often

able drug kinases been multiple have inhibit we other. our about demonstrate that talked this and oncogenic We these also pathways. key We to inhibiting key

you downstream we that want level to PDGFR-alpha S-Y-K BTK. fully course, And at another We've then and about BTK, in ERK. of talked to so show want we So see. dose SYK, to able the inhibit been of those one look is we far. down

to we it or cell interstate a see some show that we've of in I three. as and and to make as one, that mentioned able assay kinases the If in receptor dose surface well want and off, turning we been sure two, that that as levels, we're PIA

AML, is other the that it yet we about haven't confidently that phospho-FLTX. should move can spoken of to we An PIA assay inhibit for that in say you things believe phospho-FLTX. have us but much for, into order we that we to look One this

that assay ITD. And And inhibit. we say, I'll only innovation gives also wild type, we're just that seen it our off. seen that than that. FLTX the that's us that turn to able of we've phospho-FLTX phospho-FLTX gives can it's in you confidence a even difficult phospho-FLTX, PIA So more sense, we've Not is

to of to sense levels were for, show and AML. of a is the only will you already what the safety, are complete not achieving gives animal levels, is levels that know the models we we're the that above PK And cures the get but So having required that levels we PK look those what data.

are in And and the that'll the present. types in to totality this us its too New data on hope that's York thanks mean of joining. Thanks gives safe. you of be are we'll all for for two So you confidence to move able forward and

Matt Biegler

Thanks. questions. Thanks Absolutely. taking for my

Operator

you. Thank

McCarthy question Group. Maxim with comes Jason from next Our

now is line open. Your

Naureen Quibria

Hi, my taking Thanks this is for Naureen actually Jason. on for questions.

exactly of I PIA devil's a assay So not type of inhibition that seeing a XXX% level throughout CLL, of you're the may inefficiency, guess regarding of at have sort activity it that advocate CG-XXX the is in BTK your body? question In in I it there inhibition the BT that indicative clinical study a any concern that degree isn't capture the body of shows

and clinical at actually -- I'm at you BTK showed drug inhibition guess, quite look haven't doses more I that's quite bit because asking, which into yet now if it complete a up to hasn't they early translated one competing activity. advanced,

So my this how are confident question assay? the applicability is you guess in conversely I of clinical

William Rice

device. preaching CLL great not are just BTK are this does the active you the it because your many a indicates inhibition on hitting cells, and changes homing Oh, Inhibition choir. occasions. drug of kill But addressed the key -- hitting question are you fossil to component. that BTK you pharmacologically I've of is

them lymphoid responsible keeps cells there. So lymph BTK those is for the nodes, tissues, spleen, in and it the the maintaining

itself blood lymph that leave die. cells the respond. under BTK you you the And the directly. inhibit BTK long peripheral tissues cells for over those tend have now activity if the to then But tendency that is that they node to the patients changes term, going homing, so maintain killing inhibitor not When a the

companies, seen So two particularly Why at they'll other phospho relapsed refractory or may these or take failure levels, of inhibition deep even they three that, BTK. these four patients, in dose it until And dose see that? responses, levels this above lower is seeing start patients. you've

patients and other BTK are activated They pathways that kinase BTK enough. additional not not is mutations. because the it's have other Well, is pathways, enough, just those inhibiting

our of to complete dose BTK. responses. those they of one they had before hitting So was level showed responses. started seven their yes, But had dose before increasing actually dose think it inhibition seeing levels they continue kinases it level to They I other competitors, so four or begin

we're I your also just you. other inhibiting BTK, with is skepticism very it's inhibiting already agree in tell is So we those not reality, difference you, we're The -- and here kinases. can bounded

and some So potent kinases. less potent molecules the the of other against other against were more BTK

really inhibit have ones. they other So escalate those the to

these all levels. animal has dose more Ours kinases that key ERK, I profile the mentioned SYK, FLTX, these in all inhibiting, of against of picamolar a inhibiting these. were We're at activity range similar of much EGFR, low BTK, these

us kinases show multiple inhibit efficacy. as should that give should that these confidence So translate we into more we that

or have active other and forms that Dr. Dr. maintain also to is you overtime get it on if mutant sufficient medical of these we know the do not It's AML, should inhibitor, is is difficult sufficient date, is FLTX. in it that? responses you Perhaps time. can to see to and patients. FLTX that if to but malignancies, Bejar B-cell need And you it to known, able based kinases the to to more predict responses, and you in different confirmed an active FLTX, But in have we inhibitor Marango, be hit over to the give add observations science an that want responses response that

Jotin Marango

you, again, targets Bill well, The these one very thinking activity. and the the add by application coverage and Yeah, PIA captured apply year. perhaps highlight direction Bill kinase I the you we which versus in question, some specifically is to is going And AML. ahead us of differences just that was assay the this thank for in thing CLL the of now have between indications this when AML, later of

back drug those where required in it tyrosine Phase was just about that and the and PIA the we And were is or would and FLTX same actually this from patient of the I surrogate that clinical addition from activity. seen in previous seemed [ph] XX% And inhibition this a all activity. trials to have FLTX gilteritinib respond. have of be In more gilteritinib patient then assays that in assay for published

have one to response also Rice this is is I you a necessary, myeloid in CLL, we Dr. call BTK entirely the in that of but Bejar. not said, and disease kinases, for as And sufficient sufficient, So that's need it addition, in contrast experts we on the do. to know coincidentally Dr. is hit which other where BTK FLTX

has extra So it -- he to thoughts. any him also I'll I will pass if

Rafael Bejar

using I the tissue to the architecture important supporting we're are a doing reporter other line point the these around that the cell in and cell assays, other laboratory -- it. is the line PIA important when that mimic cells think doesn't we're make the

blood mononuclear actually and from So need also normal, we pathways is to the inhibited easier to the these the their is it of cells cells, it these in than look level in that's patient. whether plasma. have patient, reporters But drug is peripheral artificial the ability they line by you're activity if see of to right, the take those inhibit in cell markers

the us that's we better actually that that data hopefully So mechanistically -- are we're doing study a collecting inpatient. on additional these will about drugs insight give what

is more you I more with see where Marango, see that when its you be straightforward its AML, cell susceptibility, in that point And agree terms And rapid to addiction seems AML activity, in patient oncogene. or rapid inhibit responses of FLTX activated death, Dr. about we population. which to that

do But gene of or mentioned, are escape or needed that that's have as that either quickly regulation into play. can with mechanisms expression immunogenic Rice not to sufficient come there that Dr.

So to little order salvage against other to in pathways have you activity potential lasting a patient broader result that have a need in population.

Naureen Quibria

you Thank have of one It's question. all really so you. more I from much. follow-up helpful just

from the third? reportedly would up for moving third to guess rationale level sake, talk both, patient up how this count been part the that can I Thank as patient the or and the dose perhaps this first only you. dose? dose count as third moved cohort? now one him -- the patient you that's about for there's part first Or him was her -- you to you own of And mentioned a level. You would one that of my

William Rice

The one considered part answer will part is yes, of they of be and three.

want dose address to you them up move to the to Bejar would Dr. why ask to going I'm So, levels? higher

Rafael Bejar

Sure.

that the other going So, BTK that but for hit to compensatory getting levels not different same with sensitivity back we know question, potentially just we're of important is BTK enzymes Rice Dr. making drug. that the that to these the different to to to we are loss think activity. enzymes point of And your different it's prior have

patient compensatory milligrams other dose a on show twice higher day, pathways. in doses of to BTK, inhibition a XXX may for need So, in a example, inhibition where we of achieve that's order

able safe, So, the deemed that that escalate at if improve have to the to were dose that is dose level, a I drug likelihood them we if patient a might we higher think outcome level. beneficial

motivation does a chances interested also PD patient. having activity in is better the of to help hopes learn also PK that the good a It their outcome. So, to and more that opportunity do that patient increase doing And ultimately, us is the give in an this about to in achieving something of is response.

William Rice

So, purchased to dose patients think moved the patients believe I They up levels this by another company milligram and XX. down the year. of milligrams, the to got large competitor they lower our companies, good past example I XX from up is of one XX that

demonstrated I the at selected that in level PRs, B-cell point, dose dose believe patients. but efficacious correct, at and not they was responses which fully believe, a that they which not level is I felt at non-toxic. the the only they -- So, do And malignancy maybe

the safely. and long on sure respond can, dose we're to as if kinases, them that levels, to So, doing burden levels, giving these even up them make and move as because well-tolerated. patients safe certain as they're so is give again, those it's upon lower dose drug you chance much best higher need as to well, And hitting us you the to to do

Naureen Quibria

That's the Thank for you all me. you. for color. Thank

Operator

Thank you.

comes JonesTrading. question next from with Our Cross Matthew

now Your line open. is

Matthew Cross

Hey questions addressing EHA there you you guys, about from with and some CG-XXX to out appreciate the hear this call. AML good and key of program

of and very questions glad clear ASH Just situation. bit on I'm a kind wanting a for remarks the result -- blood me. comment expectation all first of your just COVID EHA I related about as expectations a guess, for you the drill to of kind we're reduction to about in few being a a introductory of made an draws that in of little -- that about here and

ASH may will a little stressed the to that draws and and given of most kind how at get to data curious EHA look EHA into that you've already be that that blood forward -- in the was may and events? have insight how of particularly PK kind more safety at for things at that just those evaluations impact may reduction started it, impact important flow PK/PD for I the going So, bit at

William Rice

Matt. This thanks Bill again. right, is All

blood Good all patients all the really that us of to steady-state. picture day by certain is on. previously that all example going samples tell we've of the is achieve So, shown what's that want we're collecting the eight, we

two, XX, day we to that the samples on So, -- eight, steady-state. one, day which hitting We we eight, then then day it understand collecting think initial of the day of the and one, make then the is cycle blood throughout well have as all all would the make -- certain so that want pharmacokinetics at day day then XX, beginning as been one, dose of day and we at XX. the end the to get

miss that, or the live steady-states, those we even of to. instance, is, all in us couple day well, of gives a between, day XX, without XX that maybe can had we've can if for decided but we we So, what

go draw sites we so into blood and coming to and drawn it trying to patients burden trial. So, if go possible, if them a We're can they site. can we're get have into clinical on the the the trying can't to remotely out have the to they or someone minimize other then back make that

these an want continue that's that what critical patients. kinases we really maintain dose of certain in and patients, have we the minimum to understanding that achieve these which It's is on can level to minimum we're steady-state these But exposure know. pharmacokinetics the with on pressure to

So, those points. are main the

collecting times, on on get the the at so going we're those for can also and the PBMCs. and to On later going samples try collect a We're we day what's one, BTK still to at read actually better also PBMCs.

your data that may question? relationships. answer provide to to we be believe all we're able So, adequately Did PK/PD correlate to the we needed -- going

Matthew Cross

That's it as that these get of I the trying more expectations sounds And I kind a know And beginning, but to glad to prior little agency. AML. on follow-up of what guess I early a forward had just your insight. me you're as discussion it as it putting handling to we're with Bill. upcoming Yes, great logical FDA, of then question a far two-part Thanks with readouts. days bit to the the color of did. around program

stratification I of kind like wondering parts, two FLTX FLTX one, standpoint, guess, from mutation, on to said standpoint, on based patients or here, intend if I from enrolling forms focus you're maybe shown across within an going just or board or be? an intent mutations a particular patients inclusion broadly therein, the is patients whichever you've focus know on may mutants, on the FLTX portion to But evidence dose focus those in to FLTX. AML there I these to escalation

preclinical you have you AML, And also you've in until be then you're a think, I very expect efficacious. shown synergies, second the would testing I'm testing particular, patients to that, other to dose to to for degree where I prudent, eager you've with sure part and was in begin venetoclax not But agents. maybe know some of because been begin combination

kind initial to from of curious kind of about it to from just we moving beginning really testing monotherapy into may what initial hope as at So, you what escalation? combination to prior the CG-XXX dose escalation and see we're the speculate drive dose outcomes, best see to

William Rice

All right.

those. through can of I get all if see Let's

Matthew Cross

to. repeat need anything I to Happy if

William Rice

no, No, okay. that's

types we're we we patients the So, this effectively effect, on genetic on comers. going we want want trial? differentiate want part, the So, are not have what patients the the all AML background patients, for first you of to based so among of agnostic, to know in mutation to to bring

very get Having be to said able most because ITD some the be love quickly. FLTX to likely will early by those that, we'd patients far responsive on

that we hope get on cohorts that's or dose try. among the levels early the patients we will So, first at to early something three would

wild that we'd well as on. mutations all in show in But to that patients have are patients, eager mutations, those of other ones as mutations, patients FLTX, to drug this with that active patients, to these particular BTKX be other those various now RAF FLTX, inhibitors, types should FLTX of type resistant like get we're against also

we it so level higher it may maybe see have entry push effective, think but of the is Now, that if dose those be to we levels some try to more be at effective here. how to the we where just dose

are answer of in to put the go can, But as the we going as this sensitive these study. to after soon but we we want yes, are question, most patient your some populations within believe it we all on value to get that patients, molecule what

we Once because then In terms of -- MDS also in to then patients combination can, we're we we going lined patients try with we've this spoken on And in focus believe studies. there. the active agent want drug began order AML come and also combination. drug patients and up, would to that likely with test quickly study AML to to immediately to single we back our to and we MDS, single then agent. can as going this In get that, expand be get as

MDS. Bejar thoughts to going Dr. of address he's So, give what his do on I'm I'm to because and going some expert the those also to ask that is on

Rafael Bejar

Yes, thanks Bill.

As usual, the leave answered follow-up. to you've question me already and

and particular right, look relationship and biology an of at to CG-XXX we its the general. AML AML exactly MTS, beyond have he's intent myeloid activity in malignancies in given the do to So, that

want drugs and dose the study expand strong performing population, have and we combinations and indications we example, we with understand patient MDS AML go venetoclax the escalation, like data other in short-term, to the in up it including to then running, that consider do get shared started before. where preclinical how for and And that

as kinase standard-of-care. that far certainly a considered and MDS This I inhibition population think not need has tyrosine would currently that use. goes, is it is is and be of part as novel the something this a

the population treatment expand options well. that really patient So, for as

William Rice

the AML go patients first we to of clacks about and why combo? talk can like into you patients AML CLL into venetoclax would patients Perhaps titration versus for the

Rafael Bejar

a venetoclax a with you risk syndrome little other cautious Right. CLL, be has become to Unlike tumor potent nature, and to bit little have agents difficult patient very activity single more that more of lysis to agent population. that can in in due things active combine where the bit of and

activity, significant in dose to much other And shown to has the risks. a toxicities. and tends In benefit when single AML, patient agent marginal very easier population, combined doesn't It safer with drug really don't especially we be only that or like venetoclax that modest same with has if in have combination, you're see hypomethylating overlapping agents agent. combining

the as has propensity to know, counts, particularly, lower neutrophils. venetoclax blood So, you

evidence population. So far, that we of in our have not CG-XXX seen B-cell any patient with

hopeful and patients. in of we're that the to So, very us quickly safely drugs AML allow together that kind put understand two would to how combination

William Rice

the terms with Thank apply the that could what patients malignancies the for we've And ask then Dr. if he to B-cell also in selection the in for you. we combinations. patients Marango, I of of learned additional AML AML? would has input any

Jotin Marango

you, and thank Bill Matt, you, question. thank for the Yes,

we the of or about was New in in where it. about months lot drug, about from ago, the lot drug around about the heard of this activity held experts discussed As A but we at of point, in relapsed, are City, AML two three symposium this how that in [Indiscernible] how thinking field we you this issues this population. are also some refractory a thinking open the a York and

and that open driving our are like was feedback strategy. our discussions the it's that positioning And which also exactly and like that,

resistance, are there hanging RAF. of out so Bejar some mentioned, patients they received needs mutations, And clinical Dr. of and are problematic the FLTX that there BTKX, fruit three inhibitors as of within sort relapse, so sort before, patients Rice have Dr. sort unaddressed very populations with intolerance, lower

study this I should be separate All in captured then of and then lead able be to these could pragmatically, to Phase investigations.

know, you staged the is A most targeted agents As for traditional path approach, right? this agent typically like hematology. an a in

all a fast you other accelerated These that in start or therapies. disease, intolerant be as So, to development disease approval. monotherapy could to present path relapsed/refractory substance resistant

one. call Let's stage that

parallel, steps would can combinations and and have expansions many frontline. few indications, towards towards stage following and then behind, then closely, but which be And hematology not this a And towards move AML. two, potentially you CLL in quite expansion the in including And of right type B-cell here. CLL, actually then AML, both combination the and frontline. that is these as see something as two hand-in-hand, go likely to that tumors And path would apply well you're to

William Rice

Thank you.

Matthew Cross

Great. and super with you all there some guys in input. helpful that's appreciate No, chiming

think venetoclax with looking describe maybe, you very frontline these see indications usage. with the two different differences kind and of and may to combining forward it's then I to very the path ahead much that cogent and but even

safe stay and really So, guys. all the appreciate insight

William Rice

Thank you.

Matt. Thanks too. You

Operator

you. Pantginis next Joe line open. Thank with Your comes question from our And is Wainwright H.C.

Unidentified Analyst

guys, Hi is Joe. line the of from Pasquale this

on questions So, few trial. the from XXX a me

of in MYC-associated these basically, So, looking plasma at patients? are genes you the

William Rice

I'm we looking sorry, difficulty at what the you're in are was -- patient's saying? is specific genes that -- it

Unidentified Analyst

Are looking specific in at you genes MYC-associated the these of patients? plasma

William Rice

understand I'm I not fully your question. sure

from measuring variety other patients. well these as of We're are we MYC of the a expression levels So, as genes. PBMCs collecting

gene the patients. doing that that these expression are in says, -- yes by we -- So,

a in the all PBMCs' include at, looking looking we're because of MYC. number expression We But haven't doesn't at that out we levels. primarily the yes, are genes it reported genes other MYC

Unidentified Analyst

genes with pathway, associated these that correct? And is are MYC

William Rice

are Some not, yes. some are,

are of we're but you in these be expect other might inhibit altered interested some there genes MYC, that So, also using. you if

Unidentified Analyst

basically, question other AML MYC So, be the associated words, the defined is population? what would second genetic specific optimal signature my with in a So, is, XXX entity? there AML target

William Rice

be Actually, I think MYC AML to patients. known overexpressed in is subgroups of different many

for what patients who would think are we hopefully is I look overexpressing MYC.

expressing even sensitive looked we've as hem be as reasons solid are tend and drug. in that other well to lines both talked into overexpressing about over MYC So, That's as are to the the that malignancies. cell tumors, possibly more AML, MYC, one malignancy in out in we've those of other expanding

is are we to known difficult also into lymphoma MYC-driven. We're Right trough, COVID, but driven to trying that it's MYC. be Burkitt AML now expand with the expand. is indications that are heavily other to There want by one may that maintain to

to your likely might hope I to focus look question. respond that we most ultimately to answered in this. patients that's So, where

Unidentified Analyst

go -- basically yes, okay ahead. Yes,

William Rice

I and didn't that to anything know Dr. add wants if to MDS? Bajer AML

Rafael Bejar

that I be able say would samples we're to those just collecting answer questions. the to

decide do this in if that capture order we'll mix might predefined to want we it. we're a to understand treat, is haven't in there who We patient patients for so be a But that that to definitely we able and be such signature characterize looking responses. in it population segment, that the

William Rice

that's Yes, great.

know So, just in MYC. we going happen other down knock don't what's -- you words when to

past So, in all toxic. have been have designed to inhibit quite that the been the that MYC drugs other

will at you known do so. down selectively to least can -- MYC happen and knock not it's So, clinically, if yet what safely

we're eager we're So, looking that -- find to out.

Unidentified Analyst

a Is helpful. select very patients MYC expression? way that's to Yes, it with for

William Rice

expression, what With I'm sorry?

Unidentified Analyst

I at With if wondering MYC expression? selecting like of the way biomarker-specific using forward, MYC? thinking going was patients you're

William Rice

look one literally there is expression to PBMC. very quickly out the best We're The able MYC in itself. do that to

was said earlier lymphoma. So, one of those, I Burkitt as

those a types hopefully this want know we inhibitor, that MYC those. at look we'd Now of is to select patients and

us let patience. some data in collect AML, With

Let think do data us that. correlates like -- be support that's and I get clinical not time, over with MYC sensitivity levels. see with true, but higher would that I'd to to into the activity if the inhibition dose as yet have we

data. So, have to collect we'll the

Unidentified Analyst

Yes, much. perfect. Thank you so

William Rice

Thank you.

Operator

showing in at to the for the turn I'd Dr. I'm queue Rice remarks. questions And back further you. this Thank to like no closing call time.

William Rice

want particularly the right. came to us thank I for thoughtful want thank everyone questions And I this all afternoon. that All to us. Well, you say to joining for insightful,

much and the our gratified recruit patients these have and two us, to times. of even trials we're that both we've been clinical programs escalate of about ahead our in progress difficult new in dosing and clinical Although, work XXX able XXX our we

the for investigators, call. team, our that are our of our our analysts I look And although to it's thank this patients EHA, see forward particularly thank to evening updated you and with safe. going virtual. want in to hope on I We to be to and shareholders and support you on this the much. progress. everyone very important great We clinical their appreciate Thank health want you have a our We keeping be work.

Operator

concludes and Thank call. today's you. Ladies that gentlemen, conference

wonderful disconnect and a You have day. may all

William Rice

you. Thank